JPH0725850A - ｓＰＬＡ２阻害剤である１Ｈ−インドール−３−アセトアミド - Google Patents

ｓＰＬＡ２阻害剤である１Ｈ−インドール−３−アセトアミド

Info

Publication number
JPH0725850A
JPH0725850A JP6077650A JP7765094A JPH0725850A JP H0725850 A JPH0725850 A JP H0725850A JP 6077650 A JP6077650 A JP 6077650A JP 7765094 A JP7765094 A JP 7765094A JP H0725850 A JPH0725850 A JP H0725850A
Authority
JP
Japan
Prior art keywords
indole
methyl
alkyl
phenylmethyl
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP6077650A
Other languages
English (en)
Japanese (ja)
Inventor
Nicholas J Bach
ニコラス・ジェイムズ・バック
Robert D Dillard
ロバート・ディレイン・ディラード
Susan E Draheim
スーザン・エリザベス・ドラヘイム
Robert B Hermann
ロバート・ベル・ハーマン
Richard W Schevitz
リチャード・ウォルター・シェビッツ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of JPH0725850A publication Critical patent/JPH0725850A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP6077650A 1993-04-16 1994-04-15 ｓＰＬＡ２阻害剤である１Ｈ−インドール−３−アセトアミド Pending JPH0725850A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US4862993A 1993-04-16 1993-04-16
US048629 1993-04-16
US20872194A 1994-03-15 1994-03-15
US208721 1994-03-15

Publications (1)

Publication Number Publication Date
JPH0725850A true JPH0725850A (ja) 1995-01-27

Family

ID=26726342

Family Applications (1)

Application Number Title Priority Date Filing Date
JP6077650A Pending JPH0725850A (ja) 1993-04-16 1994-04-15 ｓＰＬＡ２阻害剤である１Ｈ−インドール−３−アセトアミド

Country Status (25)

Country Link
US (1) US5684034A (enExample)
EP (1) EP0620215B1 (enExample)
JP (1) JPH0725850A (enExample)
KR (1) KR100317755B1 (enExample)
CN (1) CN1068588C (enExample)
AT (1) ATE183503T1 (enExample)
AU (1) AU676884B2 (enExample)
BR (1) BR9401482A (enExample)
CA (1) CA2121323A1 (enExample)
CO (1) CO4230092A1 (enExample)
CZ (1) CZ289750B6 (enExample)
DE (1) DE69420068T2 (enExample)
DK (1) DK0620215T3 (enExample)
ES (1) ES2138648T3 (enExample)
FI (1) FI941767A7 (enExample)
GR (1) GR3031783T3 (enExample)
HU (1) HUT70836A (enExample)
IL (1) IL109311A0 (enExample)
NO (1) NO300732B1 (enExample)
NZ (1) NZ260298A (enExample)
PL (1) PL181319B1 (enExample)
RU (1) RU2162463C2 (enExample)
TW (1) TW268942B (enExample)
UA (1) UA44218C2 (enExample)
YU (1) YU20194A (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998037069A1 (en) * 1997-02-20 1998-08-27 Shionogi & Co., Ltd. Indole dicarboxylic acid derivatives
JPH11322713A (ja) * 1998-04-17 1999-11-24 Eli Lilly & Co 置換三環式化合物
JPH11322745A (ja) * 1998-04-17 1999-11-24 Eli Lilly & Co 置換三環式化合物およびそれを含有する組成物
EP2044958A2 (en) 2001-03-19 2009-04-08 Shionogi & Co., Ltd. Pharmaceutical composition for treating arteriosclerosis
JP2009514959A (ja) * 2005-11-04 2009-04-09 アミラ ファーマシューティカルス，インコーポレーテッド ５−リポキシゲナーゼ活性化タンパク質（ｆｌａｐ）阻害剤

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
US6252084B1 (en) 1994-03-15 2001-06-26 Eli Lilly And Company 1H-indole-3-acetamide sPLA2 inhibitors
PT675110E (pt) * 1994-04-01 2002-11-29 Lilly Co Eli 1h-indole-3-glioxilamidas inibidoras da spla2
US6214876B1 (en) 1994-07-21 2001-04-10 Eli Lilly And Company Indene-1-acetamide sPLA2 inhibitors
US5641800A (en) * 1994-07-21 1997-06-24 Eli Lilly And Company 1H-indole-1-functional sPLA2 inhibitors
AU717430B2 (en) * 1996-08-26 2000-03-23 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6630496B1 (en) 1996-08-26 2003-10-07 Genetics Institute Llc Inhibitors of phospholipase enzymes
US6713645B1 (en) * 1996-10-30 2004-03-30 Eli Lilly And Company Substituted tricyclics
CA2269203A1 (en) * 1996-10-30 1998-05-07 Nicholas James Bach Substituted tricyclics
US6569539B2 (en) 1996-10-30 2003-05-27 Tetra Level Holdings & Finance S.A. Gas barrier packaging laminate method for production thereof and packaging containers
US5919774A (en) * 1996-12-10 1999-07-06 Eli Lilly And Company Pyrroles as sPLA2 inhibitors
US6828344B1 (en) 1998-02-25 2004-12-07 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6916841B2 (en) 1998-02-25 2005-07-12 Genetics Institute, Llc Inhibitors of phospholipase enzymes
AU3297099A (en) * 1998-02-25 1999-09-15 Genetics Institute Inc. Inhibitors of phospholipase a2
TR200002446T2 (tr) * 1998-02-25 2000-12-21 Genetics Institute, Inc. Fosfolipaz enzimlerinin inhibitörleri
BR9908275A (pt) * 1998-02-25 2000-10-24 Genetics Inst Inibidores de enzimas fosfolipase
US6500853B1 (en) 1998-02-28 2002-12-31 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6407104B1 (en) 1998-03-31 2002-06-18 Shionogi & Co., Ltd. Pyrrolo[1,2-a]pyrazine spla2 inhibitor
HUP0103546A3 (en) 1998-05-21 2002-12-28 Shionogi & Co Pyrrolo[1,2-b]pyridazine derivatives having spla2 inhibitory effect and pharmaceutical compositions thereof
AU5331499A (en) * 1998-08-03 2000-02-28 Eli Lilly And Company Indole spla2 inhibitors
ES2263283T3 (es) 1998-08-03 2006-12-01 ELI LILLY & COMPANY Inhibidores de spla2 indol.
AU6240099A (en) 1998-08-24 2000-03-14 Susan E Draheim Methods and compositions for treating periodontal disease with an inhibitor of secretory phospholipase A2
DE69931963D1 (de) 1998-10-14 2006-07-27 Shionogi & Co Spla2-inhibitoren zur behandlung von ischämischen reperfusionsschäden
US6448284B1 (en) 1998-12-22 2002-09-10 Eli Lilly And Company Substituted tricyclics
US6706752B1 (en) 1999-07-19 2004-03-16 Eli Lilly And Company sPLA2 inhibitors
WO2001005789A1 (en) 1999-07-19 2001-01-25 Shionogi & Co., Ltd. TRICYCLIC COMPOUNDS HAVING sPLA2-INHIBITORY ACTIVITIES
ATE350367T1 (de) * 1999-07-19 2007-01-15 Lilly Co Eli Spla2 inhibitoren
WO2001009130A1 (en) 1999-08-02 2001-02-08 Shionogi & Co., Ltd. TRICYCLIC COMPOUNDS HAVING sPLA2-INHIBITORY ACTIVITIES
US6787545B1 (en) 1999-08-23 2004-09-07 Shiongi & Co., Ltd. Pyrrolotriazine derivatives having spla2-inhibitory activities
EP1220839B1 (en) * 1999-09-20 2006-12-06 Eli Lilly And Company Hydroxyfunctional amide 1h-indole derivatives active as spla2 inhibitors
US6831095B1 (en) 1999-09-20 2004-12-14 Eli Lilly And Company Hydroxyfunctional amide 1h-indole derivatives active as sPLA2 inhibitors
AU7559600A (en) * 1999-10-15 2001-04-23 Shionogi & Co., Ltd. V type and/or x type spla2 inhibitors
US6756376B1 (en) 1999-11-15 2004-06-29 Shionogi & Co., Ltd. Tricyclic azaindolizine derivatives having an sPLA2-inhibitory activities
DE19962300A1 (de) * 1999-12-23 2001-06-28 Asta Medica Ag Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
WO2002000646A1 (en) * 2000-06-27 2002-01-03 Smithkline Beecham Corporation Fatty acid synthase inhibitors
AU2001267825A1 (en) 2000-06-29 2002-01-08 Shionogi And Co., Ltd. Remedies for cirrhosis
WO2002000621A1 (en) * 2000-06-29 2002-01-03 Shionogi & Co., Ltd. Compounds exhibiting x-type spla2 inhibiting effect
US20050203166A1 (en) * 2000-06-30 2005-09-15 Cancer Research Technology Limited Indole-3-acetic acid derivatives
GB0016162D0 (en) * 2000-06-30 2000-08-23 Cancer Res Campaign Tech Indole-3-acetic acid derivatives
JP2004503586A (ja) * 2000-07-14 2004-02-05 イーライ・リリー・アンド・カンパニー 敗血症の治療方法
IE20010784A1 (en) * 2000-08-24 2003-04-16 Univ Dublin City N-benzylindole-3-acetic acid derivatives
DE60126831D1 (de) * 2000-12-18 2007-04-05 Lilly Co Eli Benz(g)indole und deren verwendung als spla2 inhibitoren
AU2002233928A1 (en) * 2000-12-18 2002-07-01 Eli Lilly And Company Cycloalkylfused (g)-indole compounds as spla2-inhibitors in the treatment of inflammatory diseases
US7101875B2 (en) 2001-12-03 2006-09-05 Wyeth Methods for treating arthritic disorders
US7605156B2 (en) 2001-12-03 2009-10-20 Wyeth Methods for the use of inhibitors of cytosolic phospholipase A2
US6984735B2 (en) 2001-12-03 2006-01-10 Wyeth Process for making an aldehyde
US6635771B2 (en) 2001-12-03 2003-10-21 Wyeth N-benzhydryl indole compounds
US6797708B2 (en) 2001-12-03 2004-09-28 Wyeth Inhibitors of cytosolic phospholipase A2
US7713964B2 (en) 2001-12-03 2010-05-11 Wyeth Llc Methods for treating asthmatic conditions
US7129264B2 (en) * 2003-04-16 2006-10-31 Bristol-Myers Squibb Company Biarylmethyl indolines and indoles as antithromboembolic agents
US20070161698A1 (en) * 2003-05-30 2007-07-12 Microbia, Inc. Modulators of CRTH2 Activity
CA2530808A1 (en) * 2003-07-01 2005-01-13 Microbia, Inc. Cox-2 and faah inhibitors
WO2005037227A2 (en) * 2003-10-16 2005-04-28 Microbia, Inc. Selective cox-2 inhibitors
US7417063B2 (en) * 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
US20050234244A1 (en) * 2004-04-20 2005-10-20 Wilmin Bartolini Synthesis of COX-2 and FAAH inhibitors
US20050234030A1 (en) * 2004-04-20 2005-10-20 Wilmin Bartolini Modulators of CRTH2, COX-2 and FAAH
TW200718687A (en) 2005-05-27 2007-05-16 Wyeth Corp Inhibitors of cytosolic phospholipase A2
EP1931632A4 (en) * 2005-08-18 2011-05-11 Microbia Inc USEFUL INDOOR CONNECTIONS
EP1948602A2 (en) * 2005-11-03 2008-07-30 Ilypsa, Inc. Indole compounds having c4-amide substituents and use thereof as phospholipase-a2 inhibitors
US7666898B2 (en) 2005-11-03 2010-02-23 Ilypsa, Inc. Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors
US8048880B2 (en) * 2007-05-03 2011-11-01 Anthera Pharmaceuticals, Inc. Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
WO2010127099A2 (en) 2009-04-29 2010-11-04 Amarin Corporation Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
CN105384619B (zh) * 2014-08-22 2020-05-29 四川海思科制药有限公司 一种异丙基苯酚衍生物及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2825734A (en) * 1955-04-11 1958-03-04 Upjohn Co Reduction of carbonylic radicals in indolyl-3 compounds
US2890223A (en) * 1956-03-22 1959-06-09 Research Corp 1-benzyl, 2-methyl, 5-methoxy tryptamine
US3196162A (en) * 1961-03-13 1965-07-20 Merck & Co Inc Indolyl aliphatic acids
US3242163A (en) * 1961-03-13 1966-03-22 Merck & Co Inc Indolyl aliphatic acids
US3242193A (en) * 1961-03-13 1966-03-22 Merck & Co Inc Indolyl aliphatic acids
US3242162A (en) * 1961-03-13 1966-03-22 Merck & Co Inc Indolyl aliphatic acids
US3271416A (en) * 1961-10-24 1966-09-06 Merck & Co Inc Indolyl aliphatic acids
US3259622A (en) * 1962-09-07 1966-07-05 Merck & Co Inc 1-benzyl-3-indolyl-alpha-haloalkyl and alkylidenyl acetic acids
US4428962A (en) * 1981-10-30 1984-01-31 Schering Corporation Indoles in treatment of peptic ulcers
EP0299076A4 (en) * 1987-01-23 1991-01-09 Yoshitomi Pharmaceutical Industries, Ltd. 5-hydroxyindole-3-carboxamide compound and medicinal use thereof
US5145845A (en) * 1991-05-14 1992-09-08 Warner-Lambert Co. Substituted 2-carboxylindoles having pharmaceutical activity
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998037069A1 (en) * 1997-02-20 1998-08-27 Shionogi & Co., Ltd. Indole dicarboxylic acid derivatives
JPH11322713A (ja) * 1998-04-17 1999-11-24 Eli Lilly & Co 置換三環式化合物
JPH11322745A (ja) * 1998-04-17 1999-11-24 Eli Lilly & Co 置換三環式化合物およびそれを含有する組成物
JP2000026416A (ja) * 1998-04-17 2000-01-25 Eli Lilly & Co 置換された三環式化合物
EP2044958A2 (en) 2001-03-19 2009-04-08 Shionogi & Co., Ltd. Pharmaceutical composition for treating arteriosclerosis
JP2009514959A (ja) * 2005-11-04 2009-04-09 アミラ ファーマシューティカルス，インコーポレーテッド ５−リポキシゲナーゼ活性化タンパク質（ｆｌａｐ）阻害剤

Also Published As

Publication number Publication date
CZ89394A3 (en) 1994-12-15
FI941767A0 (fi) 1994-04-15
PL181319B1 (pl) 2001-07-31
ES2138648T3 (es) 2000-01-16
DE69420068D1 (de) 1999-09-23
ATE183503T1 (de) 1999-09-15
GR3031783T3 (en) 2000-02-29
RU2162463C2 (ru) 2001-01-27
CO4230092A1 (es) 1995-10-19
NO941361L (no) 1994-10-17
HU9401060D0 (en) 1994-07-28
CN1098715A (zh) 1995-02-15
YU20194A (sh) 1997-09-30
FI941767L (fi) 1994-10-17
TW268942B (enExample) 1996-01-21
AU676884B2 (en) 1997-03-27
NO300732B1 (no) 1997-07-14
UA44218C2 (uk) 2002-02-15
CA2121323A1 (en) 1994-10-17
HUT70836A (en) 1995-11-28
NO941361D0 (no) 1994-04-15
DK0620215T3 (da) 1999-12-06
BR9401482A (pt) 1994-10-18
CN1068588C (zh) 2001-07-18
IL109311A0 (en) 1994-07-31
NZ260298A (en) 1996-05-28
DE69420068T2 (de) 1999-12-23
CZ289750B6 (cs) 2002-03-13
EP0620215A1 (en) 1994-10-19
KR100317755B1 (ko) 2002-08-09
AU5949294A (en) 1994-10-20
US5684034A (en) 1997-11-04
EP0620215B1 (en) 1999-08-18
FI941767A7 (fi) 1994-10-17

Similar Documents

Publication Publication Date Title
JPH0725850A (ja) ｓＰＬＡ２阻害剤である１Ｈ−インドール−３−アセトアミド
JP3621128B2 (ja) ｓＰＬＡ２阻害剤１Ｈ−インドール−３−酢酸ヒドラジド
EP0772592B1 (en) 1H-INDOLE-1-FUNCTIONAL sPLA 2 INHIBITORS
US5733923A (en) 1H-indole-3-glyoxylamide sPLA2 inhibitors
NO170482B (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive karboksamid-derivater
JP2002522386A (ja) インドールｓＰＬＡ２インヒビター
US6252084B1 (en) 1H-indole-3-acetamide sPLA2 inhibitors
US6831095B1 (en) Hydroxyfunctional amide 1h-indole derivatives active as sPLA2 inhibitors
JP2002522385A (ja) インドールｓＰＬＡ２インヒビター
US6391908B1 (en) Oxime amide indole type sPLA2 inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20031203

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20040302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040630

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20040824

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20041203

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20060406